Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track TVTX with free AI briefings, catalyst countdowns, and dilution alerts.

TVTX · Travere Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$471.8M Cash on Hand
CF+ Cash Runway
Follow TVTX by email Get an email when TVTX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about TVTX, unsubscribe in one click. Privacy

📣 What TVTX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Sparsentan (RE-021)
FDA approved Feb 2023 · Filspari
Proteinuria Phase 4 · NCT07219121 Active not recruiting
Fosmetpantotenate Pantothenate Kinase-Associated Neurodegeneration Phase 3 · NCT03041116 Terminated
Pegtibatinase Homocystinuria Phase 3 · NCT06247085 Recruiting
No sparsentan Proteinuric Renal Disease Phase 1 · NCT07224776 Recruiting

Also used in these trials (approved or third-party drugs, not TVTX's own candidates): Dapagliflozin, Irbesartan.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

TVTX holds $471.8M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when TVTX files for a raise →

👥 Who Owns TVTX

Insiders 1.5% Institutions (458 holders) 98.5% Public and other holders 0%
HolderTypeShares% of sharesAs of
FMR LLC Institution (13G, 5%+) 5,707,883 5.95% 2026-09-30
BANK OF AMERICA CORP /DE/ Institution (13G, 5%+) 5,439,155 5.67% 2026-06-30
Vanguard Capital Management Institution (13G, 5%+) 4,699,424 4.90% 2026-03-31
Eric M Dube
CHIEF EXECUTIVE OFFICER, Director · +351,425 options
Insider 432,886 0.45% 2026-10-15
Peter Heerma
EVP, CHIEF COMMERCIAL OFFICER · +78,061 options
Insider 117,066 0.12% 2026-09-15
Elizabeth E Reed
Chief Legal Officer and GC · +4,250 options
Insider 105,389 0.11% 2026-09-15
Jula Inrig
EVP, Head of R&D & CMO · +82,355 options
Insider 100,491 0.10% 2026-09-15
William E. Rote
Chief Research Officer · +4,250 options
Insider 98,197 0.10% 2026-09-15
Jeffrey A Meckler
Director · +12,000 options
Insider 91,500 0.10% 2026-09-10
Christopher R. Cline
CHIEF FINANCIAL OFFICER · +4,250 options
Insider 87,508 0.09% 2026-09-15
Gary A Lyons
Director · +12,000 options
Insider 61,500 0.06% 2026-08-17
Timothy Coughlin
Director · +12,000 options
Insider 56,250 0.06% 2026-06-12

Share count 95,992,155 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📅 Past FDA Decisions & Stock Reactions

DateDrugTypeRun-up 30dDecision 1dAfter 5d
2026-04-13 FILSPARI NDA +1.7% +6% +40.8%
2026-01-13 — sNDA -0.8% -14.6% -18.1%

Browse all historical PDUFA outcomes →

Get the full TVTX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TVTX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.